Log in
Enquire now
MetacrineSciences

MetacrineSciences

A biotechnology company with a focus on pharmaceuticals that treat liver and gastrointestinal diseases. It was founded in 2014 and is located in San Diego, California.

OverviewStructured DataIssuesContributors

Contents

metacrine.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Consumer biotechnology
Consumer biotechnology
Chemistry
Chemistry
Drug metabolism
Drug metabolism
Enzyme kinetics
Enzyme kinetics
Pharmacokinetics
Pharmacokinetics
...
Location
San Diego
San Diego
0
B2X
B2C
B2C
CEO
‌
Preston Klassen
0
Email Address
investors@metacrine.com0
Phone Number
+185836978000
Full Address
3985 Sorrento Valley Blvd., Suite C, San Diego, CA 92121
4225 Executive Square, Suite 600 San Diego, CA 920370
Investors
ArrowMark Partners
ArrowMark Partners
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners
EcoR1 Capital
EcoR1 Capital
venBio
venBio
Invus
Invus
Lilly Asia Ventures
Lilly Asia Ventures
Vivo Capital
Vivo Capital
Deerfield Management
Deerfield Management
...
Founded Date
2014
Fax Number
(858) 369-78250
Total Funding Amount (USD)
87,000,000
Latest Funding Round Date
June 2018
Stock Symbol
MTCR0
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
Ronald M. Evans
0
‌
Jeff Jonker
0
‌
Preston Klassen
0
‌
John Mchutchison
0
‌
Julia C. Owens
0
‌
Andrew Guggenhime
0
‌
Amir Nashat
0
‌
Richard Heyman
0
Latest Funding Type
Series C
Series C
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
65,000,000
About

Metacine is a San Diego-based company that specializes in the research and development of drugs for liver and gastrointestinal (GI) diseases, such as nonalcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease.

Product

The company has multiple programs running for the research and development of its products. Its FXR

agonist program is designed for NASH and IBD and is in the Phase 2 and Phase 1 of clinical trials for each respective disease. The SSAO/VAP-1 Inhibitor program is an inflammatory target and is in the pre-clinical stage of development. Its HSD17B13 inhibitor is also for NASH and is in the lead optimizations stage.

The drug from its FXR agonist program is called MET409 and has seen success when it was administered in different dosages along with a placebo group. When the drug was dosed at 80 milligrams to patients, researchers saw a 55% reduction in relative mean liver fat content in the patients.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients

https://www.prnewswire.com/news-releases/metacrine-demonstrates-best-in-class-fxr-drug-program-with-positive-clinical-results-in-nash-patients-300990991.html

Web

January 22, 2020

Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures

https://www.globenewswire.com/news-release/2019/09/18/1917271/0/en/Metacrine-Secures-50-Million-Growth-Capital-Facility-from-K2-HealthVentures.html

Web

September 18, 2019

References

Find more companies like MetacrineSciences

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.